• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Verily

7 innovative digital health offerings to treat diabetes

September 28, 2022 By Sean Whooley

MIT Insulin Dosing device diabetes

From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out. Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty. Moving away from the physical device, innovations in the digital diabetes space continue […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Better Therapeutics, dariohealth, Dexcom, Diabetes, Glytec, Onduo, One Drop, Sword Health, Verily, Virta Health, Zillion

Verily’s Onduo, Sword Health collaborate on virtual diabetes care

August 17, 2022 By Sean Whooley

Logos of Verily Onduo and Sword Health

Onduo announced today that it entered into a strategic collaboration with Sword Health to broaden virtual care for diabetes and other conditions. Sword Health, a digital musculoskeletal (MSK) care provider, will work with Onduo by Verily, an Alphabet sister company of Google. The idea is to offer complementary solutions, broadening access to virtual care benefits […]

Filed Under: Business/Financial News, Diabetes, Featured, Technology Tagged With: Google, Onduo, Sword Health, Verily

Dexcom inks $250m amended deal with Verily for next-gen diabetes tech

November 21, 2018 By Sarah Faulkner

Dexcom

Dexcom (NSDQ:DXCM) said yesterday that it plans to pay $250 million upfront in stock to Verily in an amended collaboration and licensing deal. The two companies are working to develop a second-generation continuous glucose monitoring system. The updated deal also notes that the companies could collaborate on additional products and software. The new agreement structure makes […]

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: DexCom Inc., Verily

Sensile Medical partners with Verily, Sanofi to develop connected insulin patch pump

June 27, 2018 By Sarah Faulkner

Sensile Medical

Swiss medical device-maker Sensile Medical announced this week that it struck a deal with Verily and Sanofi (NYSE:SNY) to develop and commercialize a connected insulin patch pump. The pre-filled insulin patch pump will be designed primarily for people with Type II diabetes, according to the Olten, Switzerland-based company. Each company brings its own unique strength to […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, sensilemedical, Verily

Here’s how Sanofi separates true innovation from all the hype in digital health

May 18, 2018 By Sarah Faulkner

Sanofi logo

Recognizing that digital technology is here to stay in the business of healthcare, pharmaceutical companies have not shied away from collaborating with the folks in Silicon Valley. Sanofi (NYSE:SNY), for instance, has dove in feet first, striking deals with major tech players like Verily. But weeding out true disruptions from all the noise isn’t easy. “There’s […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Sanofi-Aventis, Verily

Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

May 1, 2018 By Sarah Faulkner

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases. By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, […]

Filed Under: Clinical Trials, Diagnostics, Discovery, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, Verily

Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies

January 30, 2018 By Sarah Faulkner

National Institutes of Health logo

The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, GlaxoSmithKline plc, michaeljfoxfoundation, National Institutes of Health, Pfizer Inc., Sanofi-Aventis, Verily

Onduo taps Glytec’s insulin therapy software as part of virtual diabetes clinic

November 29, 2017 By Sarah Faulkner

Glytec

Glytec has inked a deal with Onduo to integrate the company’s Glucommander Outpatient insulin management software into Onduo’s virtual diabetes clinic. Onduo, a joint venture of Sanofi (NYSE:SNY) and Verily, is reportedly working to develop a platform that brings together medical devices, software and support from healthcare experts to help people manage their Type II diabetes. The […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Glytec, Onduo, Sanofi-Aventis, Verily

Verily launches biosensor-equipped Study Watch for clinical study patient monitoring

April 17, 2017 By Fink Densford

Verily's Study Watch

Verily Life Sciences, the medical arm of Google parent Alphabet (NSDQ:GOOGL), today unveiled its Study Watch, a wearable device designed to passively capture health data. The watch, intended to create a method of unobtrusive biosensing, is equipped with multiple sensors, including an electrocardiogram, and can monitor heart rate, electrodermal activity and inertial movements, with a battery life of up […]

Filed Under: Business/Financial News, Clinical Trials, Patient Monitoring Tagged With: Google, Verily

Sanofi, Google’s Verily launch $500m Onduo diabetes JV

September 12, 2016 By Brad Perriello

Sanofi, Verily form Onduo

Sanofi (NYSE:SNY) and Verily Life Sciences, the healthcare play owned by Google parent Alphabet (NSDQ:GOOGL), are launching a joint venture to tackle diabetes. The Cambridge, Mass.-based Onduo JV will aim to combine Verily’s expertise in miniaturized electronics, analytics, and consumer software with Sanofi’s diabetes program. Dr. Joshua Riff, formerly senior vice president of prevention & wellbeing at UnitedHealth‘s (NYSE:UNH) Optum business, was tapped to be […]

Filed Under: Diabetes, Drug-Device Combinations, Wall Street Beat Tagged With: Onduo, Sanofi-Aventis, Verily

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS